Publication | Closed Access
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
1.1K
Citations
7
References
2008
Year
The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP. Consistent results are observed across subgroups of patients.
| Year | Citations | |
|---|---|---|
Page 1
Page 1